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I. INTRODUCTION
Obesity-induced chronic inflammation is critical in the pathogenesis of insulin resistance and subsequently leads to diabetes, cardiovascular disease, and several types of cancer. Although several previous studies have demonstrated that a CCR2
antagonist improved obesity induced insulin resistance, 10, 11 there has been no study investigating the effect of a dual CCR2/CCR5 antagonist on obesity induced chronic inflammation and insulin resistance. PF4178903 is a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist (CCR2 and CCR5 binding IC50 values = 3.0 and 5.3 nM, respectively). 12 Therefore, we investigated whether a dual CCR2/CCR5 antagonist, PF4178903, attenuates inflammation and insulin resistance in obesity by regulating both adipose macrophage recruitment and M1/M2 status.
Mice
Eight-week-old 40 male C57BL/6J mice (Charles River Laboratories, Yokohama, Japan) were divided into four groups and fed for 12 weeks as follows: 
Isolation of adipose tissue-infiltrating cells
Mouse epididymal adipose tissue was minced and digested at 37℃ with shaking in PBS supplemented with 1mg/ml collagenase type 2 (Sigma) for 40 minutes. The digested tissue was filtered through a 100 µm nylon mesh to remove undigested tissue and centrifuged at 1,500 rpm for 5 min. The stromal vascular fraction (SVF) was obtained from the resulting pellet.
Flow cytometry
Immune cells isolated from epididymal adipose tissues were incubated with were used for CBAs.
Enzyme-linked immunosorbent assay (ELISA)
The mice were euthanized after an 8-h fast, and blood was collected through cardiac puncture. Serum cholesterol, triglyceride, glucose, and insulin levels were measured levels at time of sacrifice. Serum glucose, total cholesterol and triglyceride concentrations were determined using commercially available enzymatic assay kits (Asan Pharmacology, Seoul, Korea). Serum insulin levels were measured using an ultrasensitive mouse insulin ELISA kit (Shibayagi, Gunma, Japan), and the serum adiponectin level was measured using an ELISA kit (AdipoGen Inc., Seoul, Korea). Homeostatic model assessment of insulin resistance (HOMA-IR) was calculated as fasting serum insulin (mU/L) × fasting plasma glucose (mg/dl)/405.
Western blot analysis
The epididymal adipose tissue of each mouse was dissected and immediately frozen in liquid nitrogen. Lipids were removed by centrifugation at 10,000 × g for 20 min. Total protein (50 μg) was subjected to Western blot using various polyclonal antibodies. The intensities of the bands were measured with an Image J Analyzer (Biocompare, San Francisco, CA, USA).
Cell culture
RAW264.7 macrophages (ATCC, USA) were grown at 37℃ in 5% CO₂ in RPMI1640 medium (Gibco BRL, NY, USA) containing 10% fetal calf serum, 10ml/L penicillin streptomycin (Invitrogen, Carlsbad, CA) and medium was changed every 2 days. Free fatty acids (oleic acid, 250 μM, Sigma-Aldrich) were dissolved in ethanol containing bovine serum albumin (BSA, 50 μM) and conjugated with BSA at a 10:1 molar ratio before use.
Isolation of adipose tissue-conditioned medium
Mesenteric adipose tissue was isolated from C57BL/6 male mice (8 weeks old; Koatech Ltd., Gyeonggi-do, Korea) fed HFD for 2 months. All subsequent procedures were performed in a laminar-flow hood. The adipose tissue was minced into fragments less than 10 mg in weight and cultured. Briefly, 500 mg of tissue was seeded in 10 ml of serum-free medium in the wells of a 100mm dish, and the dish was placed in a humidified incubator at 37℃ and 5% CO2 for 3 days.
Migration assay
Cell migration was evaluated in a multi-well micro chemotaxis chamber (Neuro Probe). RAW264.7 macrophages cells were suspended in either RPMI 1640, adipose tissue conditioned medium (ATCM), or CCL2 and CCL4 at a concentration of 1×10 4 cells/ml, and then 60 ul of each solution was placed in the upper layer of a 96-well chamber membrane whose lower well contained or did not contain PF4178903. Following incubation at 37℃ for 4 h, the cells that had not migrated were removed, and the cells that had migrated across the filter were fixed, stained with Diff-Quik (International Reagent Corp, Darmstadt, Germany),
and counted (n=4).
Statistical analyses
All data are presented as mean ± SEM. Statistical analysis was performed using a one-way analysis of variance (ANOVA) and Tukey's test for multiple comparisons, using SPSS version 20.0 software (SPSS Inc., Chicago, IL, USA).
Differences were considered statistically significant at P < 0.05.
III. RESULTS
Obesity increases both CCR2 and CCR5 expression in adipose tissue macropahges
To investigate the roles of CCR2 and CCR5 in obesity, we analyzed CCR2
and CCR5 expression in epididymal white adipose tissue using The number of transmigrated peritoneal macrophages was measured using a -14 -migration assay in the presence and absence of PF4178903. Original magnification is x200 (scale bar = 100 μm).*P < 0.05 compared to control. #P < 0.05 compared to CCL2, CCL4 or ATCM treated -15 -
PF4178903 attenuates weight gain in HFD-fed mice
To examine whether PF4178903 influenced diet-induced obesity, we investigated body weight in mice fed either a RD or HFD, both with and without PF4178903 (10 mg/kg/day), for 12 weeks. The HFD-fed mice had significantly increased body weights compared to the RD-fed mice. Body weights did not differ between the RD-fed control mice and PF4178903 treated RD-fed mice. However, the HFD-fed mice treated with PF4178903 had significantly attenuated body weight gains compared to HFD-fed control mice (Figure 3a ), whereas food intake was similar among the two groups (Figure 3b ). 
PF4178903 reduces adipocyte size in HFD-fed mice
We further examined the histological analyses of fixed epididymal adipose tissue and quantified adipocyte size. Hematoxylin and eosin staining of adipose tissue showed significant expansion in the size of adipocytes in epididymal fat of HFD-fed mice. In addition, HFD-fed mice showed crown-like structures (CLS)
which represent an accumulation of macrophages around dead adipocytes.
However, PF4178903 treatment significantly attenuated these effects (Figure 4a 
PF4178903 attenuates HFD-induced metabolic dysfunction and inflammation
To investigate the effects of PF4178903 on biochemical parameters, we measured metabolic parameters in mice. PF4178903 treatment attenuated the HFD-induced higher levels of serum glucose and insulin seen in HFD control mice. Serum levels of total cholesterol, triglyceride and HOMA-IR values were significantly lower in PF4178903 treated HFD-fed mice compared with HFD control mice. Serum adiponectin levels were higher in HFD-fed mice treated with PF4178903 compared to levels measured in HFD-fed control mice (Table 1) .
Systemic inflammation status was also evaluated, and the results showed that PF4178903 treatment markedly reduced serum levels of pro-inflammatory cytokines, including TNF-α, MCP-1 and IL-6, in HFD-fed mice (Figure 5a , b, c).
These data indicated that PF4178903 treatment inhibited HFD-induced inflammation.
-20 - 
PF4178903 attenuates HFD-induced impaired glucose tolerance and improves insulin sensitivity in adipose tissue
The result of intraperitoneal glucose tolerance test revealed that plasma glucose levels were significantly decreased in a time-dependent manner in PF4178903 treated HFD-fed mice compared to HFD-fed control mice (Figure 6a) .
Similarly, the result of insulin tolerance test revealed that PF4178903 treated HFD-fed mice displayed increased insulin sensitivity when compared with HFD control mice (Figure 6b ). Furthermore, PF4178903 treatment increased the levels of phosphorylated IRS-1 and phosphorylated AKT in white adipose tissue, which were reduced by the high fat diet (Figure 6c ). These data suggest that PF4178903 prevents HFD-induced insulin resistance. (Figure 7e-g ).
-25 - Chemokine receptors have become attractive targets for anti-obesity therapy, as interactions with their ligands mediate the recruitment of inflammatory cells to the adipose tissue, and contribute to chronic inflammation and insulin resistance. 13 Although clinical trials had been conducted to determine the effect of a CCR2 inhibitor in human metabolic diseases, these inhibitors were not developed as therapeutic agents. 14 This suggests that other chemokine receptors may also play significant roles in insulin resistance and chronic inflammation.
There is increasing evidence that CCR5 also plays a considerable role in the regulation of the adipose tissue inflammatory response to obesity. 9 As in a previous report, our results demonstrated that both CCR2 and CCR5 are expressed in adipose tissue macrophages of diet induced-obesity mice (Figure 1 ). In this background, novel agents which simultaneously antagonize multiple chemokine receptors, such as dual CCR2 /CCR5 antagonists have been developed. 15, 16 However, to date, there have been few studies investigating the effect of a dual chemokine receptor antagonist on obesity related chronic metabolic disease.
Therefore, we focused this study on the role of dual CCR2 /CCR5 antagonists in obesity and insulin resistance.
Our results showed that PF4178903 significantly improved HFD-induced metabolic dysfunction, insulin resistance and inflammation via a reduction of ATMs infiltration. Adipose tissue is an important endocrine organ. In addition to its role in storing energy, HFD-induced obesity primes inflammation in adipose tissue, suggesting that a dysfunction of adipose tissue strongly contributes to the initiation and exacerbation of insulin resistance. 17 With respect to inflammation in adipose tissue, ATMs recruitment is a critical factor in the pathogenesis of insulin resistance. 18 We observed that PF4178903 reduced crown-like structures, an indicator of the extent of macrophage recruitment and the number of dead adipocytes, 19 in the adipose tissue of HFD-fed mice. Subsequently, PF4178903 treatment reduced chronic systemic inflammation and improved insulin sensitivity via regulating ATMs recruitment in adipose tissue.
In the present study, PF4178903 significantly attenuated obesity-induced body weight gain, while it did not affect food intake. Furthermore, we observed that PF4178903 suppressed adipocyte hypertrophy in epididymal white adipose tissue, consequently increasing serum adiponectin levels in HFD-fed mice.
Oversized adipocytes release free fatty acid (FFAs) by failing to store and oversized adipocytes also release chemokines (e.g.MCP-1, CCL4). 20 The excessive release of FFAs and chemokines affects ATMs signaling by promoting pro-inflammatory activation, and a vicious circle evolves between hypertrophied adipocytes and ATMs. 21 Our in vitro result demonstrated that PF4178903 markedly inhibited chemokine induced-macrophage chemotaxis. These findings contribute to the growing evidence for cross-talk between adipocytes and macrophages in modulating immune and metabolic functions.
Dysregulation of M1/M2 polarization in macrophages as well as macrophage recruitment has become an emerging mechanism underlying the pathogenesis of obesity and insulin resistance. 22 Thus, strategies restraining M1 polarization and/or driving alternative M2 activation of macrophages may have -30 -the potential to protect against exacerbated inflammation and insulin resistance in obesity. Here, we showed that PF4178903 significantly shifted the macrophage phenotype from M1 (CD11c+) to M2 (CD206+) in HFD-induced obesity. These data imply that the dual CCR2/CCR5 blockade regulates macrophage polarization in ATMs. Although the exact mechanism of shifting macrophage phenotype by dual CCR2/CCR5 blockade can not be explained in this present study, we assume that reversed adipocyte hyperplasia and lowered adipocyte death by PF4178903 treatment causes M2 shift of macrophage. 19, 23 In addition, increased secretion of adiponectin from relatively lean phenotype adipocyte caused by PF4178903 treatment might contribute to M2 shift of macrophage. 24 Recent reports have shown that the infiltration of CD8+ T cells precedes M1-polarized macrophage recruitment, and the interactions between T cells and macrophages are considered to constitute a maladaptive feed-forward loop, which leads to adipose inflammation and insulin resistance. 25, 26 We also observed that PF4178903 specifically reduced the accumulation of CD8+ T cells but did not influence CD4+ T cells in adipose tissue (Figure 7d-f ). This finding supports the fact that changes in the immune system might precede macrophage polarization, and that ATMs might be effectors of a coordinated inflammatory response. 27 These adaptive immune responses induced by PF4178903 in obesity might be 
